Skip to Content
Merck
All Photos(1)

Key Documents

SML3240

Sigma-Aldrich

CL264

≥98% (HPLC)

Synonym(s):

2-(4-((6-Amino-2-(butylamino)-8-hydroxy-9H-purin-9-yl)methyl)benzamido)acetic acid, CL 264, CL-264, N-[4-[[6-Amino-2-(butylamino)-7,8-dihydro-8-oxo-9H-purin-9-yl]methyl]benzoyl]glycine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H23N7O4
CAS Number:
1510712-69-2
Molecular Weight:
413.43
MDL number:
MFCD32671317
UNSPSC Code:
51111800
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

General description

CL264 is a hydrophilic molecule. CL264,an adenine analog, is a potent and selective toll-like receptor 7 (TLR7) agonist with no TLR8-stimulating potency. This bioactive small molecule belongs to the category of 9-benzyl-8-hydroxyadenine derivatives. It contains a glycine molecule attached to the benzyl group. Studies show that CL264 is capable of activating NF-κB and stimulating the secretion of IFN-α in cells that express TLR7. CL264 is commonly used at a concentration range from 2 ng/mL to 10 μg/mL for stimulating cells in cultures.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

TLR7 agonist loaded airway epithelial targeting nanoparticles stimulate innate immunity and suppress viral replication in human bronchial epithelial cells
Kan
International Journal of Pharmaceutics, 5, 5:617:121586-5:617:121586 (2022)
Tobias Hilbert et al.
Mediators of inflammation, 2015, 948540-948540 (2016-01-16)
TLR7 ligation in plasmacytoid dendritic cells is promising for the treatment of cancer, allergy, and infectious diseases; however, high doses of ligands are required. We hypothesized that the combination of structurally different TLR7 ligands exponentiates the resulting immune response. CAL-1
Joseph Skurski et al.
Frontiers in cellular and infection microbiology, 10, 620392-620392 (2021-02-16)
A well-controlled innate immune response is characterized by a rapid yet self-limiting inflammatory response. Although much is known about the range of inflammatory stimuli capable of triggering an innate immune response, the mechanisms which govern the degree of inflammation induced
Jahnavi Aluri et al.
Blood, 137(18), 2450-2462 (2021-01-30)
Inborn errors of immunity (IEI) are a genetically heterogeneous group of disorders with a broad clinical spectrum. Identification of molecular and functional bases of these disorders is important for diagnosis, treatment, and an understanding of the human immune response. We
Sourav Pal et al.
European journal of medicinal chemistry, 210, 112978-112978 (2020-11-16)
Aberrant activation of the endosomal Toll-like receptor 7 (TLR7) has been implicated in myriad autoimmune diseases and is an established therapeutic target in such conditions. Development of diverse TLR7 antagonists is mainly accomplished through random screening. To correlate human TLR7
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service